Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Factors Influencing Drug Absorption: Pharmaceutical Parameters01:28

Factors Influencing Drug Absorption: Pharmaceutical Parameters

246
Solid dosage forms such as tablets and capsules undergo rigorous manufacturing processes to ensure stability and effectiveness. Their dissolution and absorption properties are influenced significantly by the choice of excipients (inactive ingredients that serve various roles in the formulation), and the methodology applied during production. The manufacturing parameters, such as compression force and granulation techniques, significantly affect dissolution rates. Elevated compression forces...
246
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

46
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
46
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

476
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
476
Factors Influencing Drug Absorption: Physicochemical Parameters01:22

Factors Influencing Drug Absorption: Physicochemical Parameters

633
The physicochemical characteristics of drugs play a crucial role in formulating stable and bioavailable drug products. The solubility of a drug, governed by the varying pH along the GI tract and its dissociation constant (pKa), is pivotal in determining its ionization state and absorption rate. Notably, weak acids and bases remain unionized and are absorbed more rapidly.
Enhanced drug absorption can be achieved by reducing particle sizes and increasing surface areas, thereby facilitating...
633
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

36
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
36
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

39
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
39

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanopatterned bioresorbable elastomeric scaffolds to promote neural, glial, and endothelial differentiation using human embryonic and induced pluripotent stem cells.

Journal of tissue engineering·2026
Same author

Physicochemical Characterization and In Vitro Activity of Poly(ε-Caprolactone)/Mycophenolic Acid Amorphous Solid Dispersions.

Polymers·2024
Same author

Self-assembled three-dimensional hydrogels based on graphene derivatives and cerium oxide nanoparticles: scaffolds for co-culture of oligodendrocytes and neurons derived from neural stem cells.

Nanoscale·2023
Same author

Lactide and Ethylene Brassylate-Based Thermoplastic Elastomers and Their Nanocomposites with Carbon Nanotubes: Synthesis, Mechanical Properties and Interaction with Astrocytes.

Polymers·2022
Same author

Novel biodegradable and non-fouling systems for controlled-release based on poly(ε-caprolactone)/Quercetin blends and biomimetic bacterial S-layer coatings.

RSC advances·2022
Same author

Crystallization Behavior and Mechanical Properties of Poly(ε-caprolactone) Reinforced with Barium Sulfate Submicron Particles.

Materials (Basel, Switzerland)·2021

Related Experiment Video

Updated: Nov 5, 2025

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

2.3K

Amorphous solid dispersions in poly(ε-caprolactone)/xanthohumol bioactive blends: physicochemical and mechanical

Oroitz Sánchez-Aguinagalde1, Emilio Meaurio1, Ainhoa Lejardi1

  • 1Department of Mining-Metallurgy Engineering and Materials Science, POLYMAT, University of The Basque Country (UPV/EHU), School of Engineering I, Plaza Ingeniero Torres Quevedo 1, Bilbao, Spain. emiliano.meaurio@ehu.eus.

Journal of Materials Chemistry. B
|May 17, 2021
PubMed
Summary

This study shows polycaprolactone (PCL) can create amorphous solid dispersions (ASDs) of xanthohumol (XH) up to 50 wt%. These ASDs maintain toughness, enabling new biomedical devices.

More Related Videos

Fabricating Superhydrophobic Polymeric Materials for Biomedical Applications
09:22

Fabricating Superhydrophobic Polymeric Materials for Biomedical Applications

Published on: August 28, 2015

19.4K
Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids
07:42

Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids

Published on: March 1, 2024

1.0K

Related Experiment Videos

Last Updated: Nov 5, 2025

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients
11:27

A Package of Established Analytical Tools to Investigate the Solid-State Alteration of Lipid-Based Excipients

Published on: August 9, 2022

2.3K
Fabricating Superhydrophobic Polymeric Materials for Biomedical Applications
09:22

Fabricating Superhydrophobic Polymeric Materials for Biomedical Applications

Published on: August 28, 2015

19.4K
Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids
07:42

Author Spotlight: Development and Characterization of Eco-Friendly Lignin-Based Microparticles for Enhanced Delivery of Bioflavonoids

Published on: March 1, 2024

1.0K

Area of Science:

  • Materials Science
  • Biomedical Engineering
  • Pharmacology

Background:

  • Xanthohumol (XH) is a bioactive compound with therapeutic potential.
  • Developing stable amorphous solid dispersions (ASDs) is crucial for enhancing drug bioavailability.
  • Polycaprolactone (PCL) is a biodegradable polymer often used in biomedical applications.

Purpose of the Study:

  • To investigate the formation and properties of amorphous solid dispersions (ASDs) of xanthohumol (XH) in polycaprolactone (PCL).
  • To assess the miscibility and specific interactions between PCL and XH.
  • To evaluate the physical and mechanical properties of PCL/XH blends for potential biomedical applications.

Main Methods:

  • Differential Scanning Calorimetry (DSC) for miscibility and thermal analysis.
  • X-ray Diffraction (XRD) to assess crystallinity.
  • Fourier-Transform Infrared (FTIR) spectroscopy to identify specific interactions.
  • Atomic Force Microscopy (AFM) for morphological analysis.
  • Tensile testing to evaluate mechanical properties.

Main Results:

  • Successful formation of PCL/XH amorphous solid dispersions (ASDs) with up to 50 wt% XH.
  • DSC and XRD confirmed miscibility and amorphous state.
  • FTIR revealed strong specific interactions (C[double bond, length as m-dash]OO-H) between PCL and XH.
  • AFM showed composition-dependent crystalline morphology.
  • High toughness retention was observed for amorphous PCL/XH blends.

Conclusions:

  • Polycaprolactone (PCL) is a suitable matrix for creating amorphous solid dispersions (ASDs) of xanthohumol (XH).
  • The specific interactions between PCL and XH facilitate the dispersion of XH in an amorphous form.
  • These amorphous bioactive materials hold promise for developing non-stiff biomedical devices.